Stay updated with breaking news from Nasdaq Adma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of ADMA Biologics, Inc. (NASDAQ:ADMA – Get Free Report) have earned an average recommendation of “Buy” from the four analysts that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year […]
ADMA Biologics, Inc. (NASDAQ:ADMA – Get Free Report) shares reached a new 52-week high on Friday . The company traded as high as $6.80 and last traded at $6.70, with a volume of 708040 shares. The stock had previously closed at $6.74. Analyst Ratings Changes A number of equities research analysts recently weighed in on […]
ADMA Biologics (NASDAQ:ADMA – Get Free Report) will release its earnings data after the market closes on Thursday, May 9th. Analysts expect ADMA Biologics to post earnings of $0.05 per share for the quarter. ADMA Biologics has set its FY 2024 guidance at EPS and its FY 2025 guidance at EPS. ADMA Biologics (NASDAQ:ADMA – […]
ADMA Biologics, Inc. (NASDAQ:ADMA – Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 8,110,000 shares, an increase of 11.2% from the March 31st total of 7,290,000 shares. Based on an average daily trading volume, of 2,530,000 shares, the short-interest […]
Peregrine Capital Management LLC purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 882,983 shares of the biotechnology company’s stock, valued at approximately $3,991,000. Peregrine Capital Management LLC owned 0.39% of ADMA […]